Antiangiogenic and antitumor effects of Trypanosoma cruzi Calreticulin

Nandy C López1, Carolina Valck, Galia Ramírez

  • 1Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.

Abstract

Insights

Trypanosoma cruzi calreticulin (TcCRT) exhibits anti-angiogenic and anti-tumor properties, inhibiting both capillary growth and tumor development. This parasite chaperone molecule shows potential for therapeutic applications against cancer and Chagas

Area of Science:

  • Parasitology
  • Molecular Biology
  • Oncology

Background:

  • Chagas' disease, caused by Trypanosoma cruzi, affects 18 million people in Latin America.
  • Calreticulins (CRT) are multifunctional proteins involved in calcium binding and protein folding.
  • Human CRT (HuCRT) exhibits anti-angiogenic and tumor-suppressive functions.

Purpose of the Study:

  • To investigate the anti-angiogenic and anti-tumor properties of T. cruzi calreticulin (TcCRT).
  • To compare the efficacy of TcCRT with human CRT (HuCRT).
  • To explore the potential therapeutic implications of TcCRT.

Main Methods:

  • Ex vivo rat aortic ring assay for capillary growth inhibition.
  • In vitro assays using human umbilical vein endothelial cells (HUVECs) and Eahy926 cell line for capillary morphogenesis, migration, and proliferation.
  • Confocal microscopy to track TcCRT internalization by endothelial cells.
  • In vivo studies using a murine mammary tumor model.

Main Results:

  • TcCRT, particularly its N-terminal domain (N-TcCRT), abrogated capillary growth and inhibited endothelial cell functions.
  • TcCRT demonstrated greater efficacy than HuCRT in inhibiting angiogenesis.
  • TcCRT was internalized by endothelial cells, with uptake mediated by scavenger receptors.
  • TcCRT significantly inhibited the growth of a murine mammary tumor cell line in vivo.

Conclusions:

  • TcCRT possesses significant anti-angiogenic and anti-tumor properties.
  • TcCRT's anti-angiogenic capacity may contribute to its anti-tumor effects and potentially impair anti-parasite immune responses.
  • TcCRT represents a potential therapeutic candidate for cancer treatment and warrants further investigation.